Published in Drugs Aging on January 01, 2001
Neurodegenerative diseases: an overview of environmental risk factors. Environ Health Perspect (2005) 1.30
Clinical characteristics of elderly patients with a cautious gait of unknown origin. J Neurol (2005) 1.13
Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy. Neuropsychiatr Dis Treat (2012) 0.90
PROSPERA: a randomized, controlled trial evaluating rasagiline in progressive supranuclear palsy. J Neurol (2016) 0.76
Reduced Rapid Eye Movement Density in Parkinson Disease: A Polysomnography-Based Case-Control Study. Sleep (2016) 0.75
The evolution of diagnosis in early Parkinson disease. Parkinson Study Group. Arch Neurol (2000) 2.08
Parkinsonism as a manifestation of brain tumor. Surg Neurol (1985) 1.79
Essential tremor in Rochester, Minnesota: a 45-year study. J Neurol Neurosurg Psychiatry (1984) 1.69
Reversible drug-induced parkinsonism. Clinicopathologic study of two cases. Arch Neurol (1982) 1.36
Epidemiology of parkinsonism: incidence, classification, and mortality. Ann Neurol (1984) 1.34
Prevalence of movement disorders in elderly community residents. Neuroepidemiology (1994) 1.31
Dysautonomia in Parkinsonism: a clinicopathological study. J Neurol Neurosurg Psychiatry (1976) 1.21
A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology (2001) 1.20
Striatal biopterin and tyrosine hydroxylase protein reduction in dopa-responsive dystonia. Neurology (1999) 1.16
Hypersexuality with antiparkinsonian therapy. Clin Neuropharmacol (1989) 1.14
Elevated levels of DeltaFosB and RGS9 in striatum in Parkinson's disease. Biol Psychiatry (2001) 1.12
Cyanide-induced parkinsonism: a clinicopathologic report. Neurology (1985) 1.10
Relative efficacy of alcohol and propranolol in action tremor. Can J Neurol Sci (1975) 1.09
Chronic low-dose levodopa therapy in Parkinson's disease: an argument for delaying levodopa therapy. Neurology (1984) 1.07
Environmental toxins accelerate Parkinson's disease onset. Neurology (2001) 1.06
GTP-cyclohydrolase I gene mutations in hereditary progressive amd dopa-responsive dystonia. Ann Neurol (1996) 1.04
Identification of FUS p.R377W in essential tremor. Eur J Neurol (2013) 1.03
Nervous system complications of relapsing polychondritis. Neurology (1983) 0.98
Striatonigral degeneration response to levodopa therapy. J Neurol Sci (1972) 0.97
A case-control study of smoking habits, dementia, and other illnesses in idiopathic Parkinson's disease. Neurology (1987) 0.95
Tourette syndrome in Rochester, Minnesota, 1968-1979. Adv Neurol (1982) 0.95
Amantadine treatment is an independent predictor of improved survival in Parkinson's disease. Neurology (1996) 0.93
Pulmonary embolism: an under-recognized yet frequent cause of death in parkinsonism. Mov Disord (1994) 0.92
Early onset Parkinson's disease in Saskatchewan--environmental considerations for etiology. Can J Neurol Sci (1986) 0.89
Regional metal concentrations in Parkinson's disease, other chronic neurological diseases, and control brains. Can J Neurol Sci (1989) 0.87
Elevated activity of phospholipid biosynthetic enzymes in substantia nigra of patients with Parkinson's disease. Neuroscience (2001) 0.86
Cerebellar norepinephrine in patients with Parkinson's disease and control subjects. Arch Neurol (1984) 0.85
Timely levodopa (LD) administration prolongs survival in Parkinson's disease. Parkinsonism Relat Disord (1997) 0.84
Levodopa in dystonia musculorum deformans. Lancet (1973) 0.84
Drug induced dystonia tarda: treatment with L-dopa. Dis Nerv Syst (1973) 0.84
Serum antioxidant enzyme activity in Parkinson's disease. Mol Cell Biochem (1992) 0.84
Amantadine-dyazide interaction. Can Med Assoc J (1983) 0.83
Prevalence of movement disorders in institutionalized elderly. Neuroepidemiology (1995) 0.83
New use for an old drug: amantadine benefits levodopa-induced dyskinesia. Mov Disord (1998) 0.80
An independent replication of PARK16 in Asian samples. Neurology (2010) 0.80
Oxygen free radical producing activity of polymorphonuclear leukocytes in patients with Parkinson's disease. Mol Cell Biochem (1992) 0.79
Early onset Parkinson's disease and childhood environment. Adv Neurol (1987) 0.79
What is it? Case 1, 1993: parkinsonism, dysautonomia, and ophthalmoparesis. Mov Disord (1993) 0.79
Epidemiology of Parkinson's disease. Can J Neurol Sci (1984) 0.78
Age, environments, and the number of substantia nigra neurons. Adv Neurol (1990) 0.78
Epidemiological survey of dementia in parkinsonism and control population. Adv Neurol (1984) 0.78
Parkinson's disease and essential tremor. Neurology (1994) 0.77
Frequency of respiratory disorders and bradycardia in essential tremor - consideration of treatment. Parkinsonism Relat Disord (1998) 0.77
Purkinje cell loss is neither pathological basis nor characteristic of essential tremor. Parkinsonism Relat Disord (2013) 0.77
Paraquat and Parkinson's disease. Neurology (1987) 0.77
Dopa-responsive, nonprogressive juvenile parkinsonism: report of a case. Mov Disord (1997) 0.77
Amantadine: an antiparkinsonian agent inhibits bovine brain 60 kDa calmodulin-dependent cyclic nucleotide phosphodiesterase isozyme. Brain Res (1997) 0.76
Inhibition of bovine brain calmodulin-dependent cyclic nucleotide phosphodiesterase isozymes by deprenyl. Life Sci (1996) 0.76
Postural hypotension in idiopathic Parkinson's disease. Etiopathology. Neurol Neurocir Psiquiatr (1976) 0.76
Vascular pathology in male Lewis rats following short-term, low-dose rotenone administration. Vet Pathol (2009) 0.76
Death-associated protein kinase 1 variation and Parkinson's disease. Eur J Neurol (2010) 0.76
Neurological disorders and services in Saskatchewan--a report based on provincial health care records. Neuroepidemiology (1988) 0.75
Distal hereditary upper limb muscular atrophy. J Neurol Neurosurg Psychiatry (1998) 0.75
Essential leg tremor. Neurology (1990) 0.75
Gamma-aminobutyric acid (GABA)-B receptor 1 in cerebellar cortex of essential tremor. J Clin Neurosci (2012) 0.75
Parkinson's disease risk factors. Neurology (1994) 0.75
Diagnosis of PD. Neurology (1993) 0.75
Clinicopathological observations in multiple system atrophy. Mov Disord (1992) 0.75
Specificity of ethanol in essential tremor. Ann Neurol (1996) 0.75
Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q. Neurology (1999) 0.75
Polyneuropathy. Can Fam Physician (1974) 0.75
Progressive external ophthalmoplegia with Parkinsonism and Dementia. Treatment with L-dopa. Report of an autopsied case. Can J Ophthalmol (1972) 0.75
When to use levodopa in parkinsonism. Lancet (1986) 0.75
Recurrent spinal cord ischemia due to abdominal aortic aneurysm--a case report. Angiology (1989) 0.75
Multiple sclerosis presenting as isolated oculomotor nerve palsy. Can J Neurol Sci (1986) 0.75
Orthostatic hypotension. Ann Neurol (1979) 0.75
Case 1, 1996: rapidly progressive parkinsonism, incontinence, impotency, and levodopa-induced moaning in a patient with multiple myeloma. Mov Disord (1996) 0.75
Regional distribution of metals in human brain. Clin Invest Med (1987) 0.75
Letter: Parkinsonism and dementia: effects of levodopa. Lancet (1975) 0.75
Use and abuse of drugs in the elderly. Prog Neuropsychopharmacol Biol Psychiatry (1990) 0.75
EEG and urinary non-catecholic amine changes during L-dopa therapy of Parkinson's disease. Dis Nerv Syst (1972) 0.75
Brain aconitase activity is not decreased in progressive supranuclear palsy. Neurology (2002) 0.75
National conference on Parkinson's disease. Can J Neurol Sci (1991) 0.75
Bent-knee pulling in the diagnosis of lumbar root lesions. Arch Neurol (1983) 0.75
Drug therapy in common neurological disorders. Can Fam Physician (1975) 0.75
[Not Available]. Parkinsonism Relat Disord (2000) 0.75